SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277165
Filing Date
2023-11-14
Accepted
2023-11-14 16:47:00
Documents
14
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d361794d8k.htm   iXBRL 8-K 25157
2 EX-99.1 d361794dex991.htm EX-99.1 80860
6 GRAPHIC g361794g02m43.jpg GRAPHIC 10852
  Complete submission text file 0001193125-23-277165.txt   253536

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20231114.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20231114_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20231114_pre.xml EX-101.PRE 11704
8 EXTRACTED XBRL INSTANCE DOCUMENT d361794d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 231407425
SIC: 2836 Biological Products, (No Diagnostic Substances)